Objectives: To report on the accuracy of probands providing information on specific cancer types in their families and the ability of investigators to document these reports. Accurate information on the health status of family members is critical when studying familial patterns of diseases. However, collecting these data require significant resources.

Methods: We identified 143 patients with prostate cancer from the University of Texas M. D. Anderson Cancer Center who had reported at least 1 first-degree relative with cancer. There were 263 first-degree relatives identified, for whom we confirmed diagnoses using medical records, death certificates, and verbal confirmation. The data are reported in summary statistics and compared with chi-square analysis.

Results: We documented 78% of the reports, with an accuracy rate of 81.6%. We found that accuracy was highly related to the site reported. Accuracy and documentation levels were not related to the age or income of the proband. The education level was significantly associated with the ability to document cancer, but not with the accuracy of the report. The accuracy and documentation differed by the relationship of the first-degree relative to the proband.

Conclusions: Proband reporting of cancer in first-degree relatives varies widely by site, with common metastatic sites the most inaccurate. No reliable demographic factors were found that would reasonably predict the ability to document the accuracy of the report. We found a significant proportion of proband-reported prostate cancer was, in reality, benign prostatic hyperplasia. We propose a strategy of targeting male relatives and reports of cancer in common metastatic sites for aggressive follow-up.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0090-4295(01)01598-9DOI Listing

Publication Analysis

Top Keywords

prostate cancer
12
cancer
10
accuracy
8
report accuracy
8
first-degree relative
8
first-degree relatives
8
accuracy documentation
8
ability document
8
accuracy report
8
common metastatic
8

Similar Publications

Globally, the incidence and death rates associated with cancer persist in rising, despite considerable advancements in cancer therapy. Although some malignancies are manageable by a mix of chemotherapy, surgery, radiation, and targeted therapy, most malignant tumors either exhibit poor responsiveness to early identification or endure post-treatment survival. The prognosis for prostate cancer (PCa) is unfavorable since it is a perilous and lethal malignancy.

View Article and Find Full Text PDF

Some patients with metastatic castration-resistant prostate cancer (mCRPC) possess germline or acquired defects in the DNA damage repair (DDR) genes BRCA1 and BRCA2. Tumors with BRCA mutations exhibit sensitivity to poly-ADP ribose polymerase inhibitors (PARPi) such as olaparib and rucaparib. As a result, molecular diagnostic testing to identify patients with BRCA mutations eligible for the PARPi therapy has become an integral component of managing patients with mCRPC.

View Article and Find Full Text PDF

Background: To assess how centralisation of cancer services via robotic surgery influenced positive surgical margin (PSM) occurrence and its associated risk of biochemical recurrence (BCR) in cases of pT2 prostate cancer (PC).

Methods: Retrospective analysis of all radical prostatectomy (RP) cases performed in the West of Scotland during the period from January 2013 to June 2022. Primary outcomes were PSM and BCR.

View Article and Find Full Text PDF

Background: Despite extensive analysis, the dynamic changes in prostate epithelial cell states during tissue homeostasis as well as tumor initiation and progression have been poorly characterized. However, recent advances in single-cell RNA-sequencing (scRNA-seq) technology have greatly facilitated studies of cell states and plasticity in tissue maintenance and cancer, including in the prostate.

Methods: We have performed meta-analyses of new and previously published scRNA-seq datasets for mouse and human prostate tissues to identify and compare cell populations across datasets in a uniform manner.

View Article and Find Full Text PDF

This study examines remaining life expectancy (RLE) after a cancer diagnosis, focusing on age, sex, cancer type, and metabolic syndrome (MS) components, using data from the SIDIAP database in Catalonia (2006-2017). RLE was analyzed for 13 cancer types, stratified by sex and MS components. The cohort study includes 183,364 individuals followed from diagnosis until death, transfer, or study end (December 2017).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!